AI Software Improves Endovascular Thrombectomy Treatment Times for Stroke Patients

The implementation of artificial intelligence-powered large vessel occlusion (LVO) detection software for acute stroke triage can improve endovascular thrombectomy treatment times, according to new research from UTHealth Houston.

The study, which was published today in JAMA Neurology, was led by co-first authors Youngran Kim, PhD, assistant professor of management, policy, and community health with UTHealth Houston School of Public Health; and Juan Carlos Martinez-Gutierrez, MD, a former surgery fellow in the Vivian L. Smith Department of Neurosurgery with McGovern Medical School at UTHealth Houston, and as well as co-senior authors Sunil A. Sheth, MD, associate professor of neurology and director of the vascular neurology program with McGovern Medical School, and Luca Giancardo, PhD, associate professor at McWilliams School of Biomedical Informatics at UTHealth Houston.

LVO occurs when a major artery in the brain is blocked. Considered one of the more severe types of strokes, an LVO accounts for an estimated 24% to 46% of acute ischemic strokes. Prompt endovascular thrombectomy – a minimally invasive surgical procedure involving the removal of a blood clot from a blocked artery in the brain – can dramatically improve outcomes in patients with LVO acute ischemic stroke; however, its efficacy is highly time-dependent.

“The benefit of endovascular thrombectomy on functional recovery is time-sensitive, so early identification of patients with strokes with large vessel occlusions, and process improvements to accelerate in-hospital care, are critical,” Kim said. “Our study has shown that the implementation of AI software has improved workflows within the comprehensive stroke centers.”

To test how to improve in-hospital endovascular therapy workflows, researchers conducted a cluster-randomized, stepped-wedge clinical trial from Jan. 1, 2021, to Feb. 27, 2022, analyzing 243 patients with LVO stroke who presented at four comprehensive stroke centers in the Greater Houston area.

Viz LVO – artificial intelligence-enabled automated LVO detection from a computed tomography (CT) angiogram, coupled with secure messaging, was activated at the four sites in a random-stepped fashion. Once activated, clinicians and radiologists received real-time alerts to their mobile phones, notifying them of possible LVO within minutes of CT imaging completion. Members of the patient’s treatment team were also able to share information on cases in real time.

Critically, implementation of automated LVO detection software led to patients experiencing, on average, a statistically significant reduction of 11 minutes in time to thrombectomy initiation. Time from CT scan initiation to the start of endovascular therapy also fell by nearly 10 minutes.

“We are just at the beginning of automated machine-learning algorithms to benefit acute stroke care,” Giancardo said. “Many other applications are being developed, such as using CT angiograms to detect infarcted areas of the brain without advanced imaging, an NIH-funded effort by our research group which we recently published, or even the use of retina imaging as a proxy for brain imaging.”

The findings come shortly after the publication of another study led by Kim, Sheth, and other UTHealth Houston researchers, which found that, despite having worse stroke symptoms and living within comparable distances to comprehensive stroke centers, women with LVO acute ischemic stroke were less likely to be routed to the centers compared to men. Both studies are part of a broader effort to discover ways to improve stroke outcomes.

“Nearly 2 million brain cells die every minute the blockage remains, so speeding up treatments by 10 to 15 minutes can result in substantial improvements,” Sheth said. “Our study is the most rigorous of its kind to address the question of whether machine-learning software can result in a clinically meaningful improvement for patients with acute stroke, and here, we see that the answer is ‘yes.’”

Other co-authors with McGovern Medical School included Sergio Salazar-Marioni, MD; Muhammad Bilal Tariq, MD; Rania Abdelkhaleq, MPH; Arash Niktabe, BS; Anjan N. Ballekere, MS; Ananya Iyyangar, BS; Mai Le, BS; Hussain Azeem, BS; Charles Miller, PhD; Jon Tyson, MD, MPH; Sandi Shaw, RN; Peri Smith, RN; Mallory Cowan, RN; Isabel Gonzales, RN; Louise McCullough, MD, PhD; and Andrew Barreto, MD. Abdelkhaleq and Le are also with UTHealth Houston School of Public Health, and McCullough and Giancardo are also with The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.